Colossal Biosciences Stock: Will Colossal IPO or Go Extinct?
This page contains links to our partners. We may be compensated when a link is clicked. Read the disclosures to learn more.
Explore ways to buy Colossal Biosciences stock as the IPO approaches. Access pre-IPO startups like Databricks, OpenAI, and Canva via the Fundrise Innovation Fund*.
Table of Contents
Notable Colossal Biosciences News
01/15/2025: Colossal Biosciences raises $200M at $10.2B valuation
02/08/2024: We’re Bringing the Woolly Mammoth Back to Life
11/14/2023: Woolly Mammoth de-extinction project underway in Dallas
05/16/2023: How Colossal Bio Aims to ‘De-Extinct’ the Woolly Mammoth
Older news…
About Colossal Biosciences
Colossal Biosciences is a de-extinction company aiming to bring back extinct animals “on behalf of humanity, the animal kingdom, and the universe at large”.
Human expansion on Earth has led to the extinction of some species already. Scientists say up to half the world’s animal population is at risk of extinction by 2050. Earth is in the middle of a mass extinction period driven by humans.
Colossal will revolutionize history and be the first company to use CRISPR technology successfully in the de-extinction of previously lost species. On the journey we will build radical new software tools and technologies to advance the science of genomics overall.
Extinct animals on the list of de-extinction include the woolly mammoth, the Tasmanian tiger, and the dodo bird. Colossal Biosciences believes that engineering animals and reintroducing them to their previous natural habitats will help to balance ecosystems.
The company will sequence the DNA of preserved animal remains and use CRISPR technology to modify the DNA of cells of a close living relative. Then, use a surrogate species to implant an embryo for incubation.
It’s a process that’s taken decades of science and experimentation to develop. The company says that advances in de-extinction techniques may also unlock cures for human medical conditions.
Colossal Biosciences is led by tech entrepreneur Ben Lamm and genomics pioneer and Harvard and MIT professor George Church.
Here’s a video about bringing back the woolly mammoth:
Ownership
Colossal Biosciences is a venture-backed biotech startup. It has raised more than $250 million in private funding.
The latest funding round was a Series C announced in January 2025 led by TWG Global.
Venture capital investors include Tony Robbins, USIT, Breyer Capital, IQT, Draper Associates, At one Ventures, Jazz Venture Partners, Animal Capital, Global Space Ventures, Climate Capital, Winklevoss Capital, Untamed Planet, BOLD, Boost VC, Peak6, ARCH Venture Partners, Tutor Investment Corporation, and the North Dakota Development Fund (NDDF).
Funding Rounds
| Round | Date | Est. Valuation | Raise Amount | Price |
|---|---|---|---|---|
| Series C | 01/15/25 | $10.2B | $200.00M | NA |
| Series B | 01/30/23 | $1.45B | $150.00M | $ 4.39 |
| Series A | 11/18/21 | $245.00M | $65.00M | $ 1.42 |
| Seed Round | 09/12/21 | $115.00M | $15.00M | $ 1.21 |
| Source: Caplight |
Valuation
The Colossal Biosciences valuation is $10.2 billion based on the January 2025 Series C funding round that raised $200 million.
The Series B round completed in January 2023 and was estimated at a valuation of $1.5 billion.
IPO Potential
Colossal Biosciences has yet to file for an IPO and is likely many years away.
The company is still in the discovery and development phase and is likely pre-revenue. Though exciting and newsworthy, the business model of de-extinction is unclear.
Colossal Biosciences has partnerships and affiliations with conservation groups worldwide. These deep-pocked groups may eventually fund large de-extinction and species re-introductory efforts, but scientists must complete more studies before starting such unprecedented projects.
The public may be interested in supporting a company with a mission to improve humanity, so investor interest may be strong before there is a clear path to a viable business model.
News about the company taking steps toward an IPO, such as hiring an investment banking firm or “exploring options to go public,” may hit the media before then.
Please bookmark this page for the latest news regarding the Colossal Biosciences IPO date.
How to Invest in Colossal Biosciences Stock
Since Colossal Biosciences is not a public company yet, there are limited options to own equity. As the company matures and increases its private valuation, opportunities to invest may become more widespread to retail investors as early investors look to liquidate.
Accredited investors may find opportunities to invest in Colossal Biosciences stock via pre-IPO investing platforms. But most investors will need to wait until it becomes a public company, which is likely years away.
Here are some ways to increase your chances of becoming a Colossal Biosciences investor.
1. Monitor Pre-IPO Platforms to Buy Colossal Biosciences Stock
Over the past decade, a handful of pre-IPO investing platforms have emerged to bring liquidity to pre-IPO investors.
Non-accredited investors can buy early-to-late-stage pre-IPO companies by owning venture capital funds such as the Fundrise Innovation Fund. Read my review here.
The minimum to invest is $10. However, Colossal Biosciences is not a holding at this time.
Other popular pre-IPO investing platforms include Equitybee, Hiive, EquityZen, Forge Global, and Linqto.
The author has not seen evidence of Colossal Biosciences’ share availability on any pre-IPO investing platforms. Monitor them for opportunities.
Please note: This is a testimonial in partnership with Fundrise. We earn a commission from partner links on AccessIPOs.com. All opinions are my own.
2. Buy Colossal Biosciences during the IPO through a participating broker
Colossal Biosciences is likely a long way from going public. If it does, retail IPO investors can find opportunities to buy stock during the IPO, acquiring shares at the IPO price on the date before the company begins trading on the stock market.
Often reserved for Wall Street’s best customers, IPO access has become more attainable to investors in the past few years.
The online brokers in the following list give customers free access to IPOs, even with low account balances.
TradeStation has a longer track record of accessing more than 360 IPOs and secondary offerings via its partnership with ClickIPO.
Robinhood has the advantage of Silicon Valley networks and a history of getting allocations for high-profile IPOs.
Check out this list of best brokers for IPO investing to learn more about IPO access for retail investors.
3. Buy Colossal Biosciences stock after the IPO
There are advantages to waiting for any company to become publicly traded before owning it.
First, the IPO allows investors to review financials. IPO filings require detailed financial disclosures, and companies submit SEC filings each quarter as public companies. Pre-IPO investing has limited financials available.
Second, IPO stock prices typically rise with high-demand companies. You can benefit if you’re in early and sell when the price overheats.
But the stocks can fall once the first and second-quarter earnings reports become available.
Waiting for the IPO allows retail investors to gauge stock performance before buying.
Avoid buying overvalued shares immediately after the IPO. This is especially dangerous for unprofitable companies.
Shares often fall after the IPO due to lockup expirations and quarterly earnings disappointments.
However, the most disruptive companies will likely be higher in a decade. Patience pays.
Frequently Asked Questions (FAQs)
Is Colossal Biosciences Publicly Traded?
No. Colossal Biosciences is a private company.
Multiple public investable companies exist in the exciting CRISPR field, including Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. But none are focusing on de-extinction.
Mammoth Biosciences is working on medical applications of CRISPR technologies and is often confused with Colossal Biosciences.
What is the Colossal Biosciences Stock Price?
Colossal Biosciences does not have a stock price yet. The company is still private.
We can look to secondary market data providers for information on the latest stock price. The Series B round priced at $4.39 per share.
As of the latest update, a Series C round stock price has not been disclosed. Based on the valuation announcement, the stock price is estimated to be around $30 per share.
What is the Colossal Biosciences Stock Symbol?
There is no Colossal Biosciences stock symbol yet.
If and when the company files a Form S-1 with the SEC to go public, it will disclose the stock ticker.
Here are a few potential Colossal Biosciences stock tickers available in the U.S.
- COLO
- CLSL
- DODO
- MAMM
Where is the Colossal Biosciences IPO S-1 Filing?
Colossal Biosciences hasn’t submitted an S-1 filing to the SEC yet. It is unlikely to file for an IPO until it has proven it can generate substantial revenue.
We’ll post a link and embed a PDF file here when the filing goes live.
Until then, you can check out the most recent S-1 filings in our S-1 filings feed.
Colossal Biosciences News Archive
01/31/2023: Colossal Biosciences Secures $150M Series B
03/09/2022: Colossal Secures $60M Series A Funding
Conclusion
Investors get excited when they identify companies riding extraordinary macroeconomic trends (e.g., CRISPR).
This can lead us to private companies like Colossal, Mammoth, and eGenesis and the desire to own them. Colossal Biosciences is a unique company working to restore Earth’s biodiversity, and outcome investors may be interested in supporting through ownership.
However, buying the stock early on can often prove difficult for retail investors. Access and financial information to perform proper due diligence are limited, especially for a company that is still young.
Though pre-IPO investing platforms have given us more opportunities, venture capital investing is still primarily reserved for the ultra-wealthy, requiring millions to invest in seed and early funding rounds for disruptive companies.
The Fundrise Innovation Fund changes that longstanding dynamic, but Colossal Biosciences is not available in the Fund. Own it for exposure to other pre-IPO companies.
If you pursue IPO shares and early equity, maintain reasonable expectations.
If Colossal Biosciences stock is on your watch list, good luck. Invest in pre-IPO and IPO companies with caution.
Craig Stephens is a former IT professional who left his 19-year consulting career at the IRS to be a full-time finance writer. A DIY investor since 1995, he started Access IPOs in 2016 to provide a resource for ordinary investors pursuing access to IPOs. Craig studied Finance at Michigan State University and lives in Northern Virginia with his wife and three children. Learn more about Craig.
Risk Statement: Investing in IPOs and pre-IPO startups involves significant risk. Do not invest in companies based solely on what is included in this article. Only invest in IPOs and pre-IPO companies with money you can afford to lose. Access IPOs is for informational purposes only. Mentions of specific investments should not be construed as financial advice. Conduct personalized research and consider consulting with an investment advisor before investing.
